Showing results (681-690 of 1,395) with videos related to

Sort By:
Pageof 140
JCO Precision Oncology|July 27, 2023
Association Between Availability of Molecular Genotyping Results and Overall Survival in Patients With Advanced Nonsquamous Non-Small-Cell Lung CancerCharu Aggarwal, Melina E Marmarelis, Wei-Ting Hwang, et al.
JCO Precision Oncology|July 12, 2023
Comprehensive Analysis of Human Epidermal Growth Factor Receptor 2 Through DNA, mRNA, and Protein in Diverse MalignanciesAkram Mesleh Shayeb, Razelle Kurzrock, Jacob J Adashek, et al.
JCO Precision Oncology|June 14, 2023
Consensus Statements on Precision Oncology in the China Greater Bay AreaTai-Chung Lam, William Chi-Shing Cho, Joseph Siu-Kie Au, et al.
JCO Precision Oncology|June 14, 2023
Pertuzumab Plus Trastuzumab in Patients With Lung Cancer With ERBB2 Mutation or Amplification: Results From the Targeted Agent and Profiling Utilization Registry StudyApar K Ganti, Michael Rothe, Pam K Mangat, et al.
JCO Precision Oncology|June 14, 2023
Extremity Rhabdomyosarcoma-An Integrated Clinicopathologic and Genomic Study to Improve Risk StratificationHenry de Traux de Wardin, Bin Xu, Josephine K Dermawan, et al.
JCO Precision Oncology|March 25, 2026
Real-World Study Assessing Characteristics and Treatment Patterns of Patients With Human Epidermal Growth Factor Receptor 2 Immunohistochemistry 0 and Human Epidermal Growth Factor Receptor 2-Low Stage IV Breast Cancer: A Multicenter Retrospective StudyChia Jie Tan, Connor Willis, Trang Au, et al.
JCO Precision Oncology|April 30, 2026
Pertuzumab and Trastuzumab in Patients With ERBB2/3-Altered Urothelial or Ovary/Fallopian Tube Cancer: Results From the Targeted Agent and Profiling Utilization Registry StudyJohn K Chan, Michael Rothe, Elizabeth Garrett-Mayer, et al.
JCO Precision Oncology|May 6, 2026
Potential of Minimal Residual Disease in Guiding Adjuvant Therapy Decisions in Non-Small Cell Lung CancerSiyu Lei, Yaning Yang, Wenxin Jiang, et al.
JCO Precision Oncology|April 23, 2026
Does Longitudinal Targeted Panel Sequencing Provide Clinically Relevant Information in Translocation-Associated Sarcomas?Mohamed A Yakoub, Carla Saoud, Damon R Reed, et al.
JCO Precision Oncology|April 23, 2026
Inverse Relation Between Responses to Pembrolizumab Plus Chemotherapy and Subsequent Cetuximab Plus Paclitaxel in Head and Neck Cancer: Role of the Janus Kinase-Signal Transducer and Activator of Transcription Signaling PathwayKen Saijo, Hiroo Imai, Tomoyuki Iwasaki, et al.
Pageof 140